Isatuximab for transfusion-dependent anemia after transplant ABO mismatch
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests isatuximab (an anti-CD38 antibody) to help people who, after an allogeneic stem cell transplant with a major blood-type mismatch, keep needing ongoing red blood cell transfusions. It focuses on preventing or improving a condition called PRCA (a type of pure red blood cell aplasia) when the immune system isn’t producing enough new red blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 15 or older
- You had a stem cell transplant from a different person with a major ABO (blood-type) mismatch
- At about 60 days after transplant, you still need red blood cell transfusions and your reticulocyte count is low (under 10 G/L), despite good white blood cell and platelet recovery
- Your original disease has not come back (no relapse or progression), and you are not being treated for new progression
- You can use reliable birth control during the study and for at least 5 months after the last dose (and you cannot donate sperm during that time)
- You can sign consent and you (and if under 18, both parents) understand and agree to take part
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using a milder conditioning regimen and a drug called post-transplant cyclophosphamide to treat severe aplastic anemia and other acquired bone marrow failure conditions. The goal is to help patients achieve a functioning donor bone marrow with fewer side effects.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
This trial tests if a drug called luspatercept can help people with a type of aplastic anemia that requires regular blood transfusions. It may reduce how often you need transfusions by boosting your body's own blood cell production.
This trial studies a stem cell transplant approach for children with sickle cell disease, using a sibling donor whose blood type is not compatible. It aims to see if this transplant method can safely reduce serious sickle cell complications.
This trial tests whether adding a platelet-boosting medicine (rhTPO) to a standard immune-suppressing drug (cyclosporine) works better than cyclosporine alone for people with aplastic anemia who need regular blood transfusions. The goal is to improve blood counts and reduce the need for transfusions.
Hear when a new Immunological Pure Red Cell Aplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.